Report

src

Global Seasonal Influenza Market Size, Share & COVID-19 Impact Analysis, By Type (Influenza A Viruses, Influenza B Viruses, Influenza C Virus, Influenza D Viruses and Others), By Treatment (Antiviral, Neuraminidase, Inhibitors, Vaccination, and Others), By Route of Administration (Oral, Parenteral, and Others), By End-User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy), and Regional Forecasts, 2023-2030

Customization
  • We provide customized solutions to cater to your specific requirement services any region, product, or any specific market segment.
The global seasonal influenza market size was valued at USD 6.3 billion in 2022. The market is projected to grow from USD 6.3 billion in 2022 to USD 24.3 billion by 2030, exhibiting a CAGR of 21.30% during the forecast period.
 
In temperate regions of the world, seasonal influenza causes yearly epidemics that peak in the winter. It is an acute viral infection that spreads easily from person to person. As new medicines for the treatment and prevention of seasonal influenza are licensed in the upcoming years, it is anticipated that the dynamics of the seasonal influenza market will alter. Additionally, there are candidates in the pipeline for seasonal influenza in late-stage, middle-stage, and early-stage clinical development, which will increase the market size for seasonal influenza in the future. Furthermore, the recent pandemic has expedited improvements in the market for seasonal influenza. Additionally, the development of adaptable technologies will increase the demand for seasonal influenza vaccines.
 
COVID-19 IMPACT

The healthcare industry has undergone unheard-of transformations as a result of the COVID-19 epidemic. The sector is anticipated to reap the benefits of increased demand for seasonal influenza vaccines in the near future in order to boost protection against the dangerous pandemic. Improved R&D that creates a new COVID-19 vaccine is therefore anticipated to increase the market's potential for sales. The COVID-19 epidemic during the pandemic time significantly impacted market expansion. Patients must receive vaccinations for safety reasons because COVID-19 affects the respiratory system. As a result, the seasonal flu vaccine has become more common.
 
DRIVING FACTORS

Strong R&D Investments and Candidates with a Strong Pipeline to Drive Market Growth

Leading market companies like CSL Limited, Sanofi, and GlaxoSmithKline plc are investing more in R&D to improve their manufacturing capacities and concentrate on releasing new vaccines, which is what is driving the industry's continued growth. CSL Limited revealed intentions to build a new biotech manufacturing facility in Australia in November 2020. This, together with the robust vaccination pipeline and rising government financing, has made it easier to introduce therapeutically effective vaccines. Additionally, pharmaceutical firms are concentrating on funding R&D to provide new possible vaccines.
 
RESTRAINING FACTORS

Seasonal Influenza Vaccine Side Effects and a Lack of Qualified Professionals Will Both Constrain Market Expansion

Over the projection period, the growth of the worldwide seasonal influenza market may be restrained by a shortage of competent staff who cannot treat patients with the proper medications. Additionally, vaccines have a variety of adverse effects that undoubtedly slow market expansion. Side effects like fever, chills, endurance, discomfort and soreness, among many others, hamper the seasonal influenza market's expansion.
 
SEGMENTATION

By Type


Based on type, the seasonal influenza market is segmented into influenza A viruses, influenza B viruses, influenza C virus, influenza D viruses and others. The influenza A viruses category dominated the market in 2022. The most common viral cause of adults' acute respiratory distress syndrome (ARDS) is the influenza A virus. Age between 36 and 55, pregnancy, and obesity are risk factors independently linked to ARDS, whereas female sex, influenza vaccination, and infections with influenza A are protective factors (H3N2).
 
By Treatment

Based on treatment, the seasonal influenza market is segmented into Antiviral, Neuraminidase Inhibitors, Vaccination, and Others. The antiviral category dominated the market in 2022. Antiviral medications are essential in managing and preventing influenza by treating the patient's infection and preventing serious illnesses brought on by the flu, such as bacterial pneumonia. These medications limit the discharge of viral particles from infected host cells by blocking neuraminidase activity on the virus surface.
 
By Route of Administration

Based on the route of administration, the seasonal influenza market is segmented into oral, parenteral and others. The oral category dominated the market in 2022. Oral medications are anticipated to accelerate market expansion. Given that most medications are accessible in capsule and tablet form and this is a very practical mode of administration, the category is anticipated to accelerate the global market.
 
By End-Users

Based on treatment, the seasonal influenza market is segmented into hospitals, homecare, specialty clinics, and others. The hospital's category dominated the market in 2022 due to the presence of skilled professionals.
 
By Distribution Channel

Based on treatment, the seasonal influenza market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy category dominated the market in 2022. The fact that vaccinations are typically preferred and carried out at smaller institutions accounts for this dominating position. In the coming years, a high market value is anticipated partly due to the hospitals' enormous supply of vaccines.
 
REGIONAL INSIGHTS

 
North America is projected to hold the largest share of the seasonal influenza market over the forecast period. The region's market is anticipated to increase due to the quick introduction of efficient products and technologically sophisticated vaccine manufacturing facilities. Additionally, the market's expansion in North America is anticipated to be fueled by the rising occurrence of seasonal influenza and the high sales of its medication. On the other hand, the Asia Pacific seasonal influenza market is anticipated to grow significantly over the forecast period. It is projected that market expansion will be driven throughout the area by the rising number of government initiatives to offer flu vaccines and raise awareness about seasonal influenza. Additionally, the region's expanding population in nations like China and India and the desire for efficient treatments driving up sales, are anticipated to fuel market expansion.
 
LIST OF KEY COMPANIES PROFILED:
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • Mylan N.V. (U.S.)
  • Sanofi (France)
  • Boehringer Ingelheim International GmbH (Germany)
  • Merck & Co., Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Bristol-Myers Squibb Company (U.S.)
  • SHIONOGI & Co., Ltd (Japan)
  • SINOVAC (China)
KEY INDUSTRY DEVELOPMENTS
  • March 2022: Fluzone is a high-dose influenza vaccination introduced by Sanofi. The flu shot gives defense against four different types that are present in Australia.
  • September 2021: To assess the efficacy, immunogenicity, and safety of a single-dose quadrivalent mRNA vaccine against influenza in healthy individuals, Pfizer Inc. started phase 1 clinical research.
REPORT SCOPE AND SEGMENTATION
 
Attributes Details
Study Period 2016-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2016-2021
Unit Revenue (USD Million) and Volume (Kilo Tons)
Segmentation By Type, By Treatment, By Route of Administration, By End-User, By Distribution Channel and By Geography
By Type
  • Influenza A Viruses
  • Influenza B Viruses
  • Influenza C Virus
  • Influenza D Viruses
  • Others
By Treatment
  • Antiviral
  • Neuraminidase Inhibitors
  • Vaccination
  • Others
By Route of Administration
  • Oral
  • Parenteral
  • Others
By End-User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • South-east Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa
Chapter 1    Preface

    1.1    Report Scope and Description
        1.1.1    Study Purpose
        1.1.2    Target Audience
        1.1.3    USP and Key Offerings
    1.2    Key Benefits for Stakeholders
    1.3    Report Scope

Chapter 2    Report Summary

    2.1    Key Findings
        2.1.1    Top Investment Pockets
    2.2    Market Snapshot: Global Seasonal Influenza Market
    2.3    Global Seasonal Influenza Market, 2018 – 2028 (US$ Mn)

Chapter 3    COVID 19 Impact Analysis

    3.1    Impact Assessment of COVID-19 Pandemic, By Region
        3.1.1    North America: Impact of COVID-19 Pandemic
        3.1.2    Europe: Impact of COVID-19 Pandemic
        3.1.3    Asia pacific: Impact of COVID-19 Pandemic
        3.1.4    Latin America: Impact of COVID-19 Pandemic
        3.1.5    Middle-East and Africa: Impact of COVID-19 Pandemic
    3.2    Key Strategies Undertaken by Companies to Tackle COVID-19
    3.3    Quarterly Market Revenue by Region 2021 & 2022
    3.4    Pre COVID-19 Market Revenue, By Region, 2016-2019        (USD Million)
    3.5    Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    3.6    Short Term Dynamics
    3.7    Long Term Dynamics

Chapter 4    Global Seasonal Influenza Market, By Type Segment Analysis

    4.1    Seasonal Influenza Market Overview, By Type Segment
        4.1.1    Global Seasonal Influenza Market Revenue Share, By Type, 2022 & 2028 (Value, %)
    4.2    Influenza A Viruses
        4.2.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        4.2.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.2.3    Key Market Trends, Growth Factors, & Opportunities
    4.3    Influenza B Viruses
        4.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        4.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.3.3    Key Market Trends, Growth Factors, & Opportunities
    4.4    Influenza C Virus
        4.4.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        4.4.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.4.3    Key Market Trends, Growth Factors, & Opportunities
    4.5    Influenza D Viruses
        4.5.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        4.5.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.5.3    Key Market Trends, Growth Factors, & Opportunities
    4.6    Others
        4.6.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        4.6.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        4.6.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 5    Global Seasonal Influenza Market, By Treatment Segment Analysis

    5.1    Seasonal Influenza Market Overview, By Treatment Segment
        5.1.1    Global Seasonal Influenza Market Revenue Share, By Treatment, 2022 & 2028 (Value, %)
    5.2    Antiviral
        5.2.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        5.2.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.2.3    Key Market Trends, Growth Factors, & Opportunities
    5.3    Neuraminidase Inhibitors
        5.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        5.3.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.3.3    Key Market Trends, Growth Factors, & Opportunities
    5.4    Vaccination
        5.4.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        5.4.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.4.3    Key Market Trends, Growth Factors, & Opportunities
    5.5    Others
        5.5.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        5.5.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        5.5.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 6    Global Seasonal Influenza Market, By Route of Administration Segment Analysis

    6.1    Seasonal Influenza Market Overview, By Route of Administration Segment
        6.1.1    Global Seasonal Influenza Market Value Share, By Route of Administration, 2021 & 2028 (Value, %)
    6.2    Oral
        6.2.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        6.2.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        6.2.3    Key Market Trends, Growth Factors, & Opportunities
    6.3    Parenteral
        6.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        6.3.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        6.3.3    Key Market Trends, Growth Factors, & Opportunities
    6.4    Others
        6.4.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        6.4.2    Comparative Revenue Analysis, By Country, 2022 & 2028
        6.4.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 7    Global Seasonal Influenza Market, By End-User Segment Analysis

    7.1    Seasonal Influenza Market Overview, By End-User Segment
        7.1.1    Global Seasonal Influenza Market Revenue Share, By End-User, 2022 & 2028 (Value, %)
    7.2    Hospitals
        7.2.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        7.2.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.2.3    Key Market Trends, Growth Factors, & Opportunities
    7.3    Homecare
        7.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        7.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.3.3    Key Market Trends, Growth Factors, & Opportunities
    7.3    Specialty Clinics
        7.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        7.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.3.3    Key Market Trends, Growth Factors, & Opportunities
    7.3    Others
        7.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        7.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        7.3.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 8    Global Seasonal Influenza Market, By Distribution Channel Segment Analysis

    8.1    Seasonal Influenza Market Overview, By Distribution Channel Segment
        8.1.1    Global Seasonal Influenza Market Revenue Share, By Distribution Channel, 2022 & 2028 (Value, %)
    8.2    Hospital Pharmacy
        8.2.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        8.2.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        8.2.3    Key Market Trends, Growth Factors, & Opportunities
    8.3    Online Pharmacy
        8.3.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        8.3.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        8.3.3    Key Market Trends, Growth Factors, & Opportunities
    8.4    Retail Pharmacy
        8.4.1    Seasonal Influenza Share Forecast, By Region (USD Million)
        8.4.2    Comparative Revenue Analysis, By Country, 2021 & 2028
        8.4.3    Key Market Trends, Growth Factors, & Opportunities
        
Chapter 9    Seasonal Influenza Market – Regional Analysis, 2022 – 2028

    9.1    Seasonal Influenza market Overview, by Region Segment
        9.1.1    Global Seasonal Influenza market Revenue Share, By Region, 2022 & 2028
        9.1.2    Global Seasonal Influenza Market Revenue, By Region, 2017 – 2028 (US$ Mn)
        9.1.3    Global Seasonal Influenza market Revenue, By Type, 2017 – 2028 (US$ Mn)
        9.1.4    Global Seasonal Influenza market Revenue, By Treatment, 2017 – 2028 (US$ Mn)
        9.1.5    Global Seasonal Influenza Market Revenue, By Route of Administration, 2017 – 2028 (US$ Mn)
        9.1.6    Global Seasonal Influenza Market Revenue, By End-User, 2017 – 2028 (US$ Mn)
        9.1.7    Global Seasonal Influenza Market Revenue, By Distribution Channel, 2017 – 2028 (US$ Mn)
    9.2    North America
        9.2.1    North America Seasonal Influenza Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        9.2.2    North America Seasonal Influenza Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.2.3    North America Seasonal Influenza Market Revenue, By Treatment, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.2.4    North America Seasonal Influenza Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.2.5    North America Seasonal Influenza Market Revenue, By End-User, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.2.6    North America Seasonal Influenza Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.2.7    U.S. Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.2.8    Canada Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.2.9    Mexico Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    9.3    Europe
        9.3.1    Europe Seasonal Influenza Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        9.3.2    Europe Seasonal Influenza Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.3.3    Europe Seasonal Influenza Market Revenue, By Treatment, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.3.4    Europe Seasonal Influenza Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.3.5    Europe Seasonal Influenza Market Revenue, By End-User, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.3.6    Europe Seasonal Influenza Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.3.7    Germany Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.3.8    France Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.3.9    U.K. Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.3.10    Italy Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.3.11    Spain Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.3.12    Rest of Europe Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    9.4    Asia Pacific
        9.4.1    Asia Pacific Seasonal Influenza Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        9.4.2    Asia Pacific Seasonal Influenza Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.4.3    Asia Pacific Seasonal Influenza Market Revenue, By Treatment, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.4.4    Asia Pacific Seasonal Influenza Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.4.5    Asia Pacific Seasonal Influenza Market Revenue, By End-User, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.4.6    Asia Pacific Seasonal Influenza Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.4.7    China Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.4.8    Japan Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.4.9    India Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.4.10    South Korea Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.4.11    South-East Asia Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.4.12    Rest of Asia Pacific Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    9.5    Latin America
        9.5.1    Latin America Seasonal Influenza Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        9.5.2    Latin America Seasonal Influenza Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.5.3    Latin America Seasonal Influenza Market Revenue, By Treatment, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.5.4    Latin America Seasonal Influenza Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.5.5    Latin America Seasonal Influenza Market Revenue, By End-User, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.5.6    Latin America Seasonal Influenza Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.5.7    Brazil Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.5.8    Argentina Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.5.9    Rest of Latin America Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
    9.6    The Middle-East and Africa
        9.6.1    The Middle-East and Africa Seasonal Influenza Market Revenue, By Country, 2018 – 2028 (US$ Mn)
        9.6.2    The Middle-East and Africa Seasonal Influenza Market Revenue, By Type, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.6.3    The Middle-East and Africa Seasonal Influenza Market Revenue, By Treatment, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.6.4    The Middle-East and Africa Seasonal Influenza Market Revenue, By Route of Administration, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.6.5    The Middle-East and Africa Seasonal Influenza Market Revenue, By End-User, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.6.6    The Middle-East and Africa Seasonal Influenza Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn)/(Kilo Tons)
        9.6.7    GCC Countries Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.6.8    South Africa Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)
        9.6.9    Rest of Middle-East Africa Seasonal Influenza Market Revenue, 2018 - 2028 (US$ Mn)/ (Kilo Tons)

Chapter 10    Seasonal Influenza Market – Industry Analysis

    10.1    Introduction
    10.2    Market Drivers
        10.2.1    Driving Factor 1 Analysis
        10.2.2    Driving Factor 2 Analysis
    10.3    Market Restraints
        10.3.1    Restraining Factor Analysis
    10.4    Market Opportunities
        10.4.1    Market Opportunity Analysis
    10.5    Porter’s Five Forces Analysis
    10.6    PEST Analysis
    10.7    Regulatory Landscape
    10.8    Technology Landscape
    10.9      Value Chain Analysis

Chapter 11    Competitive Landscape

    11.1    Company Market Share Analysis – 2022
        11.1.1    Global Seasonal Influenza market: Company Market Share, 2022
        11.1.2    Global Seasonal Influenza Market: Company Market Share, 2022
    11.2    Strategic Developments
        11.2.1    Acquisitions & Mergers
        11.2.2    New Product Launch
        11.2.3    Regional Expansion
    11.3    Company Strategic Developments – Heat Map Analysis

Chapter 12    Company Profiles

    12.1    Pfizer Inc. (U.S.)
        12.1.1    Company Overview
        12.1.2    Key Executives
        12.1.3    Product Portfolio
        12.1.4    Financial Overview
        12.1.5    Operating Business Segments
        12.1.6    Business Segment Performance
        12.1.7    Recent Developments
    12.2    GSK plc (U.K.)
    12.3    Novartis AG (Switzerland)
    12.4    Mylan N.V. (U.S.)
    12.5    Sanofi (France)
    12.6    Boehringer Ingelheim International GmbH (Germany)
    12.7    Merck & Co., Inc. (U.S.)
    12.8    F. Hoffmann-La Roche Ltd. (Switzerland)
    12.9    Bristol-Myers Squibb Company (U.S.)
    12.10    SHIONOGI & Co., Ltd (Japan)
    12.11    SINOVAC (China)

Chapter 13    Research Methodology

    13.1    Research Methodology
    13.2    Phase I – Secondary Research
    13.3    Phase II - Data Modeling
        13.3.1    Company Share Analysis Model
        13.3.2    Revenue Based Modelling
    13.4    Phase III – Primary Research
    13.5    Research Limitations
        13.5.1    Assumptions
No Methodology
No Available